openPR Logo
Press release

Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 2024 | Sanofi Aventis, Sihuan Pharma, Sun Pharma, Taj Pharma, Shin Poong Pharma, Sawai Pharma

05-13-2020 07:08 AM CET | Health & Medicine

Press release from: Business Industry Reports

Roxatidine

Roxatidine

Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.

Global Roxatidine Market overview:

Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/268252 .

Roxatidine acetate is a specific and competitive histamine H? receptor antagonist drug that is used to treat gastric ulcers, Zollinger-Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis. The Global Roxatidine Market is segmented on the basis of Product Type, Application, End Use Industry and Region.

On the Basis of Product Type segment, the Roxatidine Market is sub segmented into Oral and Injectable. Based on End Use Industry segment, the Roxatidine Market is sub segmented into Acidity, Heartburn, Intestinal Ulcers, Stomach Ulcers and Others.

Some of the Roxatidine Market manufacturers involved in the market are Sanofi Aventis, Sihuan Pharmaceutical, Sun Pharmaceutical, Taj Pharmaceuticals, Shin Poong Pharmaceuticals, Sawai Pharmaceuticals in World, effective mergers are some of the strategies adopted by the Roxatidine Market manufacturers. New product launches and continuous technological innovations are the Roxatidine Market strategies adopted by the major players.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Roxatidine Market Report 2020" @ https://www.businessindustryreports.com/buy-now/268252/single.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

There are several manufacturers of Roxatidine in Europe and North America. In North America, the demand for Roxatidine is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/268252 .

Top Industry News:

Libtayo (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma on 05 May, 2020 -- Topline data for a pivotal, single-arm, open-label trial for Sanofi and Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced basal cell carcinoma (BCC) who had progressed on or were intolerant to prior hedgehog pathway inhibitor (HHI) therapy were announced today. Libtayo demonstrated clinically meaningful and durable responses in this group of patients for whom there are no approved treatments. Sanofi and Regeneron plan regulatory submissions in 2020.

BCC is a skin cancer and is the most common cancer worldwide, with approximately two million new cases diagnosed every year in the U.S. alone. While the vast majority of BCCs are caught early and cured with surgery or radiation, a small proportion of tumors can become advanced and penetrate deeper into surrounding tissues (locally advanced), which is more difficult to treat. Approximately 20,000 U.S. patients have advanced BCC and it is estimated that about 3,000 die each year. BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data and follows its initial U.S. approval in advanced cutaneous squamous cell carcinoma (CSCC) in 2018.

In the trial, the objective response rate (ORR) for patients (n=84) with locally advanced disease was 29% (95% CI: 19%-40%), with an estimated duration of response (DOR) exceeding one year in 85% of responders. The durable disease control rate (DCR --response or stable disease lasting at least 6 months) was 60% (95% CI: 48%-70%). In a preliminary analysis of patients (n=28) with metastatic disease, the ORR was 21% (95% CI: 8%-41%), with an estimated DOR exceeding one year in 83% of responders. The durable DCR was 46% (95% CI: 28%-66%). All data were assessed by an independent central review. Data are expected to continue to evolve with further follow-up across both patient groups.

"While PD-1 inhibitors have transformed the outlook for many patients with melanoma, progress for patients with non-melanoma skin cancers has not been as rapid," said Peter C. Adamson, M.D, Global Head of Oncology Development at Sanofi. "We are continuing to address this unmet need by first bringing Libtayo to patients with advanced cutaneous squamous cell carcinoma, and now, with this second trial, as a potential therapy for patients with advanced basal cell carcinoma. These important new results further demonstrate Libtayo's potential in patients with difficult-to-treat, non-melanoma skin cancers."

There were no new safety signals in this trial. Among the 132 patients assessed for safety (84 locally advanced and 48 metastatic), 95% of patients experienced an adverse event (AE), 32% had a serious AE and 13% discontinued due to an AE. There were 10 deaths in the locally advanced group and nine deaths in the metastatic group; none of the deaths were considered treatment-related. Sanofi and Regeneron will present additional trial findings at an upcoming medical meeting.

Table of Contents:

1 Roxatidine Product Definition
2 Global Roxatidine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Roxatidine Shipments
2.2 Global Manufacturer Roxatidine Business Revenue
2.3 Global Roxatidine Market Overview
3 Manufacturer Roxatidine Business Introduction
3.1 Sanofi Aventis Roxatidine Business Introduction
3.1.1 Sanofi Aventis Roxatidine Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 Sanofi Aventis Roxatidine Business Distribution by Region
3.1.3 Sanofi Aventis Interview Record
3.1.4 Sanofi Aventis Roxatidine Business Profile
3.1.5 Sanofi Aventis Roxatidine Product Specification
3.2 Sihuan Pharmaceutical Roxatidine Business Introduction
3.2.1 Sihuan Pharmaceutical Roxatidine Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 Sihuan Pharmaceutical Roxatidine Business Distribution by Region
3.2.3 Interview Record
3.2.4 Sihuan Pharmaceutical Roxatidine Business Overview
3.2.5 Sihuan Pharmaceutical Roxatidine Product Specification
3.3 Sun Pharmaceutical Roxatidine Business Introduction
3.3.1 Sun Pharmaceutical Roxatidine Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 Sun Pharmaceutical Roxatidine Business Distribution by Region
3.3.3 Interview Record
3.3.4 Sun Pharmaceutical Roxatidine Business Overview
3.3.5 Sun Pharmaceutical Roxatidine Product Specification
3.4 Taj Pharmaceuticals Roxatidine Business Introduction
3.5 Shin Poong Pharmaceuticals Roxatidine Business Introduction
3.6 Sawai Pharmaceutical Roxatidine Business Introduction
................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 2024 | Sanofi Aventis, Sihuan Pharma, Sun Pharma, Taj Pharma, Shin Poong Pharma, Sawai Pharma here

News-ID: 2043429 • Views: 420

More Releases from Business Industry Reports

Tetracaine Market Exhibits a Lucrative Growth Potential during 2021-2025 | Endo …
BusinessIndustryReports has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Tetracaine Market” Research Report 2021 provides an in-depth analysis of the Tetracaine with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house). The research study examines the Tetracaine on the basis of a number of criteria,
Cyber Warfare Market Evenly Poised To Reach A Market Value of US$ By Share, Size …
Overview of Global Cyber Warfare Market: This report provides in-depth study of “Global Cyber Warfare Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cyber Warfare Market report also provides an in-depth survey of key players in the market organization. According to the market research study, the Cyber Warfare is virtual conflict between state, organization, or country by the use of computer technology to disrupt activities
Covid-19 Impact on Cranio Maxillofacial Implant Market 2021-2025: Business Growt …
Overview of Global Cranio Maxillofacial Implant Market: This report provides in-depth study of “Global Cranio Maxillofacial Implant Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cranio Maxillofacial Implant Market report also provides an in-depth survey of key players in the market organization. According to the market research study, Craniomaxillofacial Implants are medical implants used in surgeries of maxillofacial region such as, head, face, neck, oral,
Beginning of the bloom: The Rise of the Biohacking Market 2021-2025 | Global Key …
Global Biohacking Market Synopsis: The report covers a forecast and an analysis of the Biohacking Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Biohacking Market along with the impact they have on the demand over the forecast

All 5 Releases


More Releases for Roxatidine

PTP Servers Market Trend and Set for Robust Growth During 2021-2027 & Covid-19 A …
Precise details related to market performance is discussed in this PTP Servers market report. It covers insights into sales effectiveness, regulatory scenarios, industry convergence, digital transformation, innovation and competitive landscape. Doing regular basis tracking of business performance is easy under the guidance of this market report. This market analysis also looks over all of the crucial potentials from business players, end purchaser and manufacturers. It further does the market classifications
Informative Report On (COVID-19 Updates) Roxatidine Market, Business Will Grow i …
According to a new report published by Allied Market Research, titled, "Roxatidine Market by Formulation (Oral and Injectable), and by Application (Acidity, Heartburn, Intestinal Ulcers, and Stomach Ulcers) - Global Opportunity Analysis and Industry Forecast, 2020-2027" The report has offered an all-inclusive analysis of the global Roxatidine Market taking into consideration all the crucial aspects like growth factors, constraints, market developments, top investment pockets, future prospects, and trends. At the
Impact of COVID-19 Outbreak on Roxatidine Market 2020| Worldwide Industry Share, …
Complete study of the global Roxatidine market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Roxatidine industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate
Roxatidine Market High trend Opportunities offers Future Business Growth by 2027 …
Roxatidine Market 2020-2027: According to a new report published by Allied Market Research, titled, "Roxatidine Market by Formulation (Oral and Injectable), and by Application (Acidity, Heartburn, Intestinal Ulcers, and Stomach Ulcers) - Global Opportunity Analysis and Industry Forecast, 2020-2027" Roxatidine is a special H2-receptor antagonist, which is mostly prescribed for reflux esophagitis, benign gastric ulcer, duodenal ulcer, and prophylaxis of recurrent ulcers. It is generally classified as an antacid, anti-reflux, or
Roxatidine Market to boost its value by year 2023 : Allied Market Research
Roxatidine is a special H2-receptor antagonist, which is mostly prescribed for reflux esophagitis, benign gastric ulcer, duodenal ulcer, and prophylaxis of recurrent ulcers. It is generally classified as an antacid, anti-reflux, or anti-ulcerant drug. The increase in prevalence of people suffering from ulcers, low cost of the drug, and its ability to lower the acid production in the stomach is expected to increase the demand for the drug. However, certain side-effects
Roxatidine Market to show Rapid Growth During 2017-2023 : Allied Market Research
Roxatidine is a special H2-receptor antagonist, which is mostly prescribed for reflux esophagitis, benign gastric ulcer, duodenal ulcer, and prophylaxis of recurrent ulcers. It is generally classified as an antacid, anti-reflux, or anti-ulcerant drug. The increase in prevalence of people suffering from ulcers, low cost of the drug, and its ability to lower the acid production in the stomach is expected to increase the demand for the drug. However, certain side-effects